Silver Book

Silver Book Fact

Staff flu vaccination reduces incidence of staff and patients

Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from 42% to 9%, and reduced nosocomial cases among hospitalized patients from 32% to 0.

Salgado C, Giannetta E, Hayden F, Farr B. Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians. Infect Control Hosp Epidemiol. 2004; 25(11): 923-8. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/preventing-nosocomial-influenza-by-improving-the-vaccine-acceptance-rate-of-clinicians/0308090E3A67BEAA74813255CC4FD456

Reference

Title
Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians
Publication
Infect Control Hosp Epidemiol
Publication Date
2004
Authors
Salgado C, Giannetta E, Hayden F, Farr B
Volume & Issue
Volume 25, Issue 11
Pages
923-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Vaccines in development 2013
    137 vaccines are currently in development in the U.S. for infectious diseases.  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Staff flu vaccination reduces incidence of staff and patients
    Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from…  
  • Shingles vaccine could improve QALY and save money
    Vaccination of 1 million people age 60 and over with the shingles vaccine would result in 11,919 non-discounted and 8,782 discounted QALYs (quality of life years) gained and save around…  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…